Drug News: A new injectable sedative/analgesic, midazolam - ScienceDirectdoi:10.1016/S0160-3450(16)33000-8SDOSAmerican Pharmacy
Data from clinical trials showed that Aikening was effective against major strains of HIV, including resistant viruses, and the efficacy was long-acting, according to the company. "As a long-acting injectable drug with a new mechanism of action, ABT has the potential to be a significant additi...
Lenacapavir(Sunlenca) received FDA approval in late 2022 as the second injectable HIV medication. It is in a new class of drugs, called capsid inhibitors, meaning that it affects the shell that protects the virus, preventing it from multiplying. Lenacapavir could cut doctor visits down to tw...
The blood-brain barrier (BBB) and the blood-cerebrospinal fluid barrier (BCSF) are two of the most complex and sophisticated concierges that defend the cen
There are currently no approved treatments for HIV or AIDS. But recently, FDAapprovedViiV Healthcare’s Cabenuva, the first and only complete long-acting injectable HIV treatment for positive adults. The drug will be administered once a month and will replace the current treatment r...
Taken every 2 months, the long-acting injectable drug cabotegravir (CAB-LA) prevented more HIV infections than daily oral pre-exposure prophylaxis (PrEP) with tenofovir/emtricitabine (TDF/FTC), according to newly announced results from a major Phase 3 study. The results were released originally ...
It is estimated that about 9.6% of these cases were extensively-drug-resistant (XDR-TB), showing additional resistance to at least one fluoroquinolone and one injectable drug (amikacin, kanamycin or capreomycin).4,6 For patients affected by XDR-TB, the therapeutic efficacy is quite limited. ...
In this study, 53% received injectable semaglutide, 31% used dulaglutide, 8% used an oral formulation of semaglutide, 6% used tirzepatide and 3% used liraglutide. Ninety-nine people (43%) received the drugs for weight management alone, while the rest also had type 2 diabetes. ...
(H1N1) viruses by applying selective drug pressure over multiple sequential passages in MDCK cells. We found that T-705 treatment did not select specific mutations in potential target proteins, including PB1, PB2, PA, and NP. Phenotypic assays based on cell viability confirmed that no T-705-...
It uses a molecule called MK-8591, which is roughly 10 times stronger as an HIV inhibitor than medicines currently on the market, and which has a very high barrier against resistance. "It slowly releases the drug and maintains a very consistent level of the drug in your body and taking th...